Does Humana Cover Qsymia (Phentermine/Topiramate ER)?
The verdict
Not Covered on most plans
Largely no. Humana's dominant line of business is Medicare Part D, and standard Medicare Part D statutorily excludes Qsymia as a weight-loss agent — this is a legal exclusion, not a formulary decision Humana can override. The notable irony: Humana has been named the central processor for the 2026 Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027), yet the Bridge does NOT cover Qsymia or any oral anti-obesity agent — it covers only specified injectable weight-loss GLP-1s (Wegovy formulations, Foundayo, and the Zepbound KwikPen). Humana has limited commercial and ACA footprint; where Humana Medicaid applies, coverage is state-dependent. Qsymia also carries significant clinical restrictions: REMS-restricted dispensing, teratogenic topiramate, and sympathomimetic cardiovascular contraindications. For most Humana readers, the Engage cash program (~$89/month) or the 2025 generic (~$63 with coupon) is the operative path. Humana cells are representative composites; verify on Humana's Medicare formulary.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Humana using your member ID.
Key facts
Humana is the central processor for the 2026 Medicare GLP-1 Bridge — but the Bridge covers only injectable weight-loss GLP-1s, not oral AOMs like Qsymia.
CMS Medicare GLP-1 Bridge fact sheet; Humana press release, 2026
Generic phentermine/topiramate ER (Teva) launched in 2025, approximately $63 with a coupon at REMS-certified pharmacies.
Drugs.com / SingleCare generic pricing, 2025
Medicare Part D has excluded weight-loss agents since 2006. The Treat and Reduce Obesity Act, which would change this, has not passed as of 2026.
CMS.gov; H.R. 4231/S. 1973, 119th Congress
Medicare vs. commercial coverage
Whether Humana covers Qsymia depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part D has statutorily excluded weight-loss agents — including Qsymia — since Part D's creation in 2006 under the Medicare Modernization Act. This exclusion applies to all Humana Medicare Advantage and Part D plans. Humana serves as the central processor for the 2026 Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027), but the Bridge does NOT include Qsymia — the Bridge covers only Wegovy formulations, Foundayo, and the Zepbound KwikPen. Changing the Medicare Part D weight-loss exclusion permanently requires an act of Congress (the Treat and Reduce Obesity Act has not passed as of 2026). Medicare members are ineligible for manufacturer copay cards under federal anti-kickback rules. The Engage home-delivery cash program (~$89/month) or the 2025 generic (~$63 with coupon at a REMS-certified external pharmacy) are the operative routes for Humana Medicare beneficiaries.
Commercial / Employer
Group & marketplace plans
Humana has a limited commercial and ACA employer footprint; its primary business is Medicare. Where Humana does offer commercial or employer plans, phentermine/topiramate ER coverage depends on whether the employer group has elected a weight-loss or AOM benefit — most have not, and standard AOM exclusions apply. Prior authorization where covered: BMI of 30 or higher, or 27 or higher with a qualifying comorbidity; behavioral program documentation; initial 4-month approval; reauthorization requires at least 3% (FDA label) or 5% (most plans) weight loss. REMS dispensing restriction; topiramate teratogenicity; sympathomimetic CV contraindication. ACA marketplace plans: AOM typically excluded. Humana Medicaid: state-dependent. All cells are representative composites; verify on Humana's formulary.
The 5 boxes you must tick to get approved
Commercial plans that will consider Qsymia require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Qsymia actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
Qsymia brand retail: approximately $206 (Drugs.com, 3.75/23mg) to $283 (SingleCare) per month. Vivus Qsymia Engage home-delivery cash program: approximately $89/month (approximately $70/month on a 90-day prescription). Generic phentermine/topiramate ER (Teva, 2025): approximately $63 with a coupon at REMS-certified pharmacies.
List price with no coverage — before any manufacturer savings card.
With coverage
Where covered on a Humana commercial or Medicaid plan with an AOM benefit, co-pays vary by formulary tier. Verify with Humana's formulary. Manufacturer savings card is NOT available to Medicare or Medicaid beneficiaries under federal anti-kickback rules.
Typical monthly copay once prior authorization is approved.
The Engage cash program is the primary route for Humana's Medicare beneficiaries. The 2025 generic is the lowest-cost option. All figures are estimates; verify with your Humana plan and preferred pharmacy. The Engage program manages REMS compliance for home delivery.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Understand that Humana Medicare Part D does not cover Qsymia — the Bridge is not the answer
If you are a Humana Medicare Advantage or Part D member, Qsymia is excluded by law and the Medicare GLP-1 Bridge does not help — the Bridge covers only injectable weight-loss GLP-1s (Wegovy, Foundayo, Zepbound KwikPen), not oral AOMs. No prior authorization will override the statutory exclusion. The Engage cash program (~$89/month) or the 2025 generic (~$63) are your routes.
- 2
For Humana commercial or Medicaid members: check your plan's AOM benefit status
Log into Humana's member portal (humana.com) and search for phentermine/topiramate or Qsymia in the drug-search tool. If no coverage appears, your plan has an AOM carve-out. Contact Humana member services (1-800-448-6262) to confirm. For Humana Medicaid members, ask your state Medicaid plan representative for the current PDL status of Qsymia in your state.
- 3
Use the Engage program or 2025 generic for the most reliable cash access
The Vivus Qsymia Engage home-delivery cash program (~$89/month; ~$70/month on a 90-day prescription) is the most reliable cash route, handling REMS dispensing through the program's own pharmacy. The generic phentermine/topiramate ER (Teva, 2025, ~$63 with coupon) is available at REMS-certified retail pharmacies. For Humana Medicare members, manufacturer savings cards are not available; these cash programs are the sole options.
Options if Humana won't cover Qsymia
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Qsymia Engage home-delivery cash program — ~$89/month
The Vivus Engage program is the primary route for Humana's Medicare-majority population, who cannot access manufacturer savings cards. Engage provides home delivery at ~$89/month (or ~$70/month on a 90-day supply) through a REMS-compliant pharmacy. Available regardless of insurance status. Contact Vivus at qsymia.com.
Generic phentermine/topiramate ER (Teva, 2025) — ~$63 with coupon
A generic entered the market in 2025 at approximately $63 with a coupon at REMS-certified pharmacies. This is the lowest-cost Qsymia equivalent for cash-paying patients, including Medicare beneficiaries.
Generic phentermine (standalone) — ~$10–$40 cash
If the topiramate combination is not clinically indicated, standalone generic phentermine is far cheaper at $10–$40 cash — though FDA-approved for only approximately 12 weeks and DEA Schedule IV.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
Largely no. Humana is Medicare-focused, and Medicare Part D excludes Qsymia by statute as a weight-loss agent. Humana runs the 2026 Medicare GLP-1 Bridge, but the Bridge covers only specified injectable weight-loss GLP-1s — not oral AOMs like Qsymia. On Humana's limited commercial and Medicaid lines, coverage is benefit-dependent and state-dependent. For most Humana members, the Engage cash program (~$89/month) or the 2025 generic (~$63 with coupon) is the realistic route.
No. The 2026 Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027) covers only Wegovy formulations, Foundayo, and the Zepbound KwikPen — all injectable weight-loss GLP-1s. Oral AOMs, including Qsymia and Contrave, are excluded from the Bridge. Humana administers the Bridge as a central processor, but administering the Bridge does not mean Humana covers Qsymia — the Bridge's drug list is set by CMS, not Humana.
Humana Medicare members who want Qsymia pay out of pocket; manufacturer savings cards are unavailable to Medicare beneficiaries under federal anti-kickback rules. The Vivus Engage home-delivery cash program is approximately $89/month (or $70/month on a 90-day prescription) and handles REMS dispensing through Engage's own pharmacy. The generic phentermine/topiramate ER (Teva, 2025) is approximately $63 with a coupon at REMS-certified pharmacies — the lowest-cost option.
All three exclude Qsymia under standard Medicare Part D by statute. Humana's distinguishing angle is the Bridge-processor irony: Humana administers the GLP-1 Bridge, yet the Bridge excludes oral AOMs. Kaiser's angle is closed-network HMO formulary limits plus Medi-Cal exclusion from 2026. Anthem's angle is the commercial employer-carve-out with a usable savings card for commercial members. For Humana's Medicare-heavy reader, the Engage program (~$89/month) or 2025 generic (~$63) is the practical answer.
A generic phentermine/topiramate ER (Teva) launched in 2025. However, the generic still faces the same Medicare Part D statutory weight-loss exclusion that applies to brand Qsymia — it is a weight-loss drug regardless of generic status. Humana Medicare plans do not cover it. On Humana commercial or Medicaid plans with an AOM benefit, the generic would be covered under standard generic tier rules. The generic at ~$63 cash is the most affordable out-of-pocket option for Humana Medicare members.
Related Articles
Does Aetna Cover Vyvanse? 2026 CVS Caremark Formulary
Aetna covers Vyvanse via CVS Caremark — generic lisdexamfetamine preferred, brand non-preferred. 70 mg/day QL per Policy 5.60.024; age-22 PA required.
Read moreDoes Kaiser Permanente Cover Qsymia? 2026 | Curex
Kaiser's closed HMO limits Qsymia access; Medi-Cal excluded weight-loss drugs in 2026. Engage cash program ~$89/mo; generic launched 2025.
Read moreDoes Aetna Cover Prolia? CVS Caremark Medical Benefit | Curex
Aetna covers Prolia under the medical benefit with PA — a q6-month clinic injection, not Part D. Jubbonti biosimilar now preferred on CVS Caremark.
Read moreDoes Anthem Cover Qsymia (Phentermine/Topiramate ER)? 2026 | Curex
Anthem covers Qsymia only if your employer elected an AOM benefit; Medicare excludes it by law. Engage ~$89/mo; generic available 2025. | Curex
Read moreDoes Aetna Cover Contrave? 2026 CVS Caremark Guide | Curex
Aetna (CVS Caremark) often excludes Contrave under AOM carve-outs. Where covered, CVS BMI prior auth applies. Medicare bars it by law. CurAccess ~$99/mo.
Read moreDoes Aetna Cover Forteo? 2026 Coverage Guide
Aetna (CVS) often excludes brand Forteo in favor of generic teriparatide or Bonsity. Teriparatide is covered with PA and bisphosphonate step therapy. 2026.
Read moreFor Humana members facing Medicare's Qsymia exclusion, a weight-management path that skips insurance is available
Medicare excludes Qsymia by law, and the Bridge only covers injectable GLP-1s — not pills. Curex offers compounded semaglutide from $49/month and compounded tirzepatide from $149/month at getcurex.com/cl/glp — no insurance, no prior authorization. Compounded semaglutide and tirzepatide are not the same medication as Qsymia. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Qsymia and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Humana before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Qsymia and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.